CVKD
NASDAQCadrenal Therapeutics Inc.
Price$2.20-0.07 (-3.08%)
01:30 PM07:30 PM
News · 26 weeks47-15%
2026-01-182026-07-12
Mix3490d
- SEC Filings16(47%)
- Insider10(29%)
- Other7(21%)
- Dividends1(3%)
Latest news
25 items- SECCadrenal Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)
- SECSEC Form D filed by Cadrenal Therapeutics Inc.D - Cadrenal Therapeutics, Inc. (0001937993) (Filer)
- SECSEC Form S-3 filed by Cadrenal Therapeutics Inc.S-3 - Cadrenal Therapeutics, Inc. (0001937993) (Filer)
- SECCadrenal Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)
- INSIDERChairman and CEO Pham Quang X sold $22,422 worth of shares (7,400 units at $3.03) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 98,589 units (SEC Form 4)4 - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)
- SECCadrenal Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)
- PRCadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules$3 million upfront with up to approximately $5.8 million of potential additional gross proceeds upon the exercise in full of warrants Net proceeds anticipated to extend cash runway into first quarter of 2027; if warrants are exercised in full for cash, it is anticipated that the cash runway would extend into second half of 2027 to advance partnering opportunities for tecarfarin in Kawasaki Disease (potential rare pediatric disease designation) and CAD-1005 in CSA-AKI and HIT PONTE VEDRA, Fla., June 30, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) (the "Company"), a biopharmaceutical company advancing late-stage novel therapies for life-threatening immune and thrombo
- SECCadrenal Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)
- INSIDERChairman, CEO and Interim CFO Pham Quang X sold $33,919 worth of shares (11,156 units at $3.04) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 105,989 units (SEC Form 4)4 - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)
- INSIDERChairman, CEO and Interim CFO Pham Quang X sold $39,829 worth of shares (11,444 units at $3.48) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 117,145 units (SEC Form 4)4 - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)
- PRCadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 CongressSelection highlights the clinical value potential of Cadrenal’s first-in-class 12-lipoxygenase inhibitor for Heparin-Induced Thrombocytopenia (HIT) First-ever randomized, blinded, placebo-controlled trial in HIT, a life-threatening blood-clotting disorder triggered by an immune reaction to heparin, the most widely used blood thinner in hospitals Phase-3 ready and addresses a peak $2 billion annual revenue potential in the HIT market PONTE VEDRA, Fla., June 24, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company advancing late-stage novel therapies for life-threatening immune and thrombotic conditions, today announced that late-breaking clinica
- INSIDERChairman, CEO and Interim CFO Pham Quang X sold $13,110 worth of shares (4,126 units at $3.18) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 128,589 units (SEC Form 4)4 - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)
- SECCadrenal Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)
- PRCadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki DiseaseCompany to present Phase 3-ready pipeline, 12-LOX platform, and pediatric rare-disease expansion to global pharmaceutical partners at the 2026 BIO International Convention in San Diego Kawasaki disease is the leading cause of acquired heart disease in children in developed nations. Patients are at risk of forming blood clots in coronary arteries and may require lifelong treatment If the designation is granted and tecarfarin is approved for this indication, Cadrenal would be eligible to receive a Priority Review Voucher—recent open-market valuations for these vouchers have reached into the ~$200 million range PONTE VEDRA, Fla., June 18, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc
- INSIDERChairman, CEO and Interim CFO Pham Quang X sold $70,352 worth of shares (18,124 units at $3.88) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 132,715 units (SEC Form 4)4 - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)
- SECSEC Form 144 filed by Cadrenal Therapeutics Inc.144 - Cadrenal Therapeutics, Inc. (0001937993) (Subject)
- PRCadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026New high-value indication for Phase 3-ready asset with data intended to support clinical development and strategic partnering discussionsAdditional billion-dollar target- Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI), a serious complication affecting 35,000 U.S. patients annually, with no approved FDA-approved targeted therapiesDual-Purpose Synergy - Planned Phase 2a proof-of-concept trial expected to generate safety, renal injury signals, and 12-LOX pathway biology in high-risk cardiac surgery patients, while generating high-value data potentially relevant to the Company's lead HIT indicationCapital-Efficient Development: Leverages shared in-hospital ICU infrastructure and an int
- INSIDERChairman, CEO and Interim CFO Pham Quang X sold $93,294 worth of shares (22,385 units at $4.17) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 150,839 units (SEC Form 4)4 - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)
- INSIDERCEO and Chairman Pham Quang X sold $36,209 worth of shares (8,285 units at $4.37) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 173,224 units (SEC Form 4)4 - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)
- SECCadrenal Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)
- PRCadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering EventLead asset CAD-1005 being researched for prevention of life-threatening blood clots in patients with Heparin-induced Thrombocytopenia (HIT), targets $2 billion peak annual revenue potential 12-LOX could play a central role in inflammatory signaling across high-impact disease areas, including diabetes, obesity, atherosclerosis, and microvascular thrombosis, and is a potential target for therapy and prevention of cancer Late-stage anticoagulant tecarfarin has U.S. Food and Drug Administration (FDA) Orphan Drug and Fast Track designations for high-risk patients with End-Stage Renal Disease (ESRD) and Atrial Fibrillation (AFib), and those patients with implanted mechanical circulatory support
- INSIDERCEO and Chairman Pham Quang X sold $3,075 worth of shares (652 units at $4.72) as part of a pre-agreed trading plan, decreasing direct ownership by 0.36% to 181,509 units (SEC Form 4)4 - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)
- INSIDERCEO and Chairman Pham Quang X sold $69,451 worth of shares (12,763 units at $5.44) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 182,161 units (SEC Form 4)4 - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)
- INSIDERCEO and Chairman Pham Quang X sold $6,629 worth of shares (1,165 units at $5.69) as part of a pre-agreed trading plan, decreasing direct ownership by 0.59% to 194,924 units (SEC Form 4)4 - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)
- PRCadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026PONTE VEDRA, Fla., May 19, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2026 Investor Conference, taking place virtually on Thursday, May 28, 2026. Company Webcast The webcast presentation will take place at 9:30 a.m. ET on Thursday, May 28, 2026. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/spring2026/ or directly at https://app.webinar.net/DxpqArQk70e. The webcast will also be avai
CVKD FAQ
6 questionsWhere does CVKD stock trade?
Cadrenal Therapeutics Inc. (CVKD) is listed on NASDAQ.What sector and industry is CVKD in?
Cadrenal Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Cadrenal Therapeutics Inc. go public?
Cadrenal Therapeutics Inc. (CVKD) completed its IPO in 2023.What are analysts saying about CVKD?
Cadrenal Therapeutics Inc. has had 1 recent analyst action on file. The most recent action was from Noble Capital Markets: Outperform with a $400.00 price target on 2023-12-18. Recent price targets cluster around $400.00.What companies are similar to CVKD?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare CVKD side-by-side with any of them on Quantisnow.How can I track CVKD on Quantisnow?
Quantisnow aggregates Cadrenal Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CVKD to receive live email and push alerts on every new disclosure.